Ferguson, Lucas http://orcid.org/0000-0001-5482-4249
Upton, Heather E.
Pimentel, Sydney C. http://orcid.org/0000-0003-2634-4322
Mok, Amanda http://orcid.org/0000-0001-6981-1547
Lareau, Liana F. http://orcid.org/0000-0003-3223-3426
Collins, Kathleen http://orcid.org/0000-0002-1712-5809
Ingolia, Nicholas T. http://orcid.org/0000-0002-3395-1545
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM130996, T32 GM007232, R35 GM130315, R35 GM130315, R01GM132104, R01GM132104, R35 GM130315)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP1 HL156819, DP1 HL156819, HL156819)
NSF | Directorate for Biological Sciences (1936069, 1936069)
Rose Hills Foundation
Article History
Received: 18 January 2023
Accepted: 23 August 2023
First Online: 2 October 2023
Competing interests
: L.F., H.E.U., S.C.P. and K.C. are named inventors on patent applications filed by the University of California describing biochemical activities of RTs used for OTTR. H.E.U. and K.C. have equity in Karnateq, which licensed the technology and is producing kits for OTTR cDNA library preparation. N.T.I. declares equity in Tevard Biosciences and Velia Therapeutics. A.M. and L.F.L. declare no competing interests.